Back to top
more

Applied Therapeutics (APLT)

(Real Time Quote from BATS)

$4.35 USD

4.35
88,947

+0.07 (1.64%)

Updated Apr 29, 2024 11:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why

by Zacks Equity Research

Applied Therapeutics (APLT) surges 124% in a month due to encouraging updates from two separate developmental programs for govorestat to treat different rare neurological indications.

Bears are Losing Control Over Applied Therapeutics Inc. (APLT), Here's Why It's a 'Buy' Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Applied Therapeutics Inc. (APLT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase

by Zacks Equity Research

Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2022.

Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition

by Zacks Equity Research

Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.

Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate

by Zacks Equity Research

Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.

Horizon (HZNP) Begins Enrollment in Alopecia Areata Study

by Zacks Equity Research

Horizon (HZNP) enrolls the first patient in a phase II study evaluating daxdilimab (HZN-7734) for the treatment of alopecia areata.

Seagen's (SGEN) Stock Up on CEO's Resignation Announcement

by Zacks Equity Research

Seagen's (SGEN) current chief executive officer and president, Clay Siegall, announces his resignation. The company is looking for a new CEO. Stock up.

Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia

by Zacks Equity Research

The FDA bestows an Orphan Drug designation to Editas' (EDIT) investigational gene therapy, EDIT-301, for treating beta thalassemia. Shares up in after-hours trading.

The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma

by Zacks Equity Research

Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma are part of Zacks top Analyst Blog

Kinjel Shah headshot

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates

by Kinjel Shah

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

Perrigo (PRGO) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Ultragenyx's (RARE) Q1 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.

Deciphera (DCPH) Down Despite Narrower-Than-Expected Q1 Loss

by Zacks Equity Research

Deciphera (DCPH) reports narrower-than-expected loss in the first quarter of 2022 while revenues beat estimates.

Apellis (APLS) Hit By Wider-Than-Expected Q1 Loss, Revenues Top

by Zacks Equity Research

Apellis' (APLS) earnings missed estimates in the first quarter of 2022, while revenues surpassed expectations.

    What Awaits Meridian Bioscience (VIVO) This Earnings Season?

    by Zacks Equity Research

    Meridian Bioscience's (VIVO) fiscal second-quarter results are likely to reflect continued strength across both its segments.

    Zosano (ZSAN) to Report Q1 Earnings: What's in the Cards?

    by Zacks Equity Research

    Zosano (ZSAN) is set to provide updates on the development path ahead for its lead candidate, M207, when it reports earnings results for first-quarter 2022.

    Why bluebird bio (BLUE) Stock Plunged 60% Year to Date?

    by Zacks Equity Research

    With no stable stream of income, bluebird bio (BLUE) faces a severe cash crunch. Moreover, the FDA extending the review period of its two regulatory filings also adds fuel to this fire.

    CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?

    by Zacks Equity Research

    On CRISPR Therapeutics' (CRSP) Q1 earnings call, investors will look for updates on its pipeline candidates, especially its lead candidate CTX001.

    Acadia (ACAD) Stock Down as Pain Candidate Misses Study Goal

    by Zacks Equity Research

    Acadia's (ACAD) phase II study, evaluating ACP-044 for treating acute pain following bunionectomy surgery, misses the primary endpoint. Stock down.

    aTyr Pharma (LIFE) Up on Orphan Drug Status for Efzofitimod

    by Zacks Equity Research

    The FDA bestows an Orphan Drug status to aTyr Pharma's (LIFE) lead candidate, efzofitimod, for the treatment of systemic sclerosis. Shares rise.

    Aeglea (AGLE) Submits BLA for a Rare Disease Drug to the FDA

    by Zacks Equity Research

    Aeglea (AGLE) files a biologics license application to the FDA for pegzilarginase to treat arginase 1 deficiency. The company has requested the FDA to grant priority review to the BLA. Shares down.

    Editas (EDIT) Begins Dosing Pediatric Patients in Gene Drug Study

    by Zacks Equity Research

    Editas (EDIT) doses the first patient pediatric patient in the BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10).

    Aptinyx (APTX) Tanks as Neuropathic Pain Study Misses Goal

    by Zacks Equity Research

    Aptinyx's (APTX) phase IIb study evaluating the effects of NYX-2925 in patients with painful diabetic peripheral neuropathy misses the primary endpoint. Stock falls sharply.

      Bristol Myers (BMY) Gets EC Nod for CAR T Cell Therapy Breyanzi

      by Zacks Equity Research

      The European Commission grants marketing authorization to Bristol Myers' (BMY) Breyanzi for treating certain forms of relapsed or refractory large b-cell lymphoma.

      Here's Why You Should Retain Universal Health (UHS) Stock Now

      by Zacks Equity Research

      Increased admissions at both of its operating segments, constant initiatives to bolster its care network and adequate cash generation abilities are likely to drive Universal Health (UHS).